期刊
PEDIATRIC NEPHROLOGY
卷 35, 期 9, 页码 1787-1789出版社
SPRINGER
DOI: 10.1007/s00467-020-04585-5
关键词
Hyperoxaluria; Stiripentol; Metabolic disorders; End-stage renal disease; Dialysis
资金
- Projekt DEAL
Background Primary hyperoxaluria type 1 (PH1) is a multisystemic metabolic disorder caused by an excessive production of oxalate by the liver. The majority of patients presenting in early infancy have end-stage renal disease (ESRD). While awaiting the results of sRNAi trials, the current standard treatment is combined liver-kidney transplantation. Recently, Stiripentol has been reported as a promising drug in the treatment of primary hyperoxaluria by reducing urinary oxalate (U-Ox). Stiripentol is an anti-convulsive drug used in the treatment of children suffering from Dravet syndrome. It causes blockage of the last step in oxalate production by inhibition of hepatic lactate dehydrogenase 5 (LDH5). Case We administered Stiripentol as compassionate use in an anuric infant with dialysis-dependent PH1 over a period of 4 months. Although achieving plasma concentrations of Stiripentol that were recently reported to lower U-Ox excretion, we did not observe significant reduction to plasma oxalate concentrations (P-Ox). Conclusion We conclude that Stiripentol may not be useful to reduce P-Ox in PH patients with advanced chronic kidney disease (CKD), but larger studies are needed to confirm this finding.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据